Eileen M Barry

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4945591/publications.pdf

Version: 2024-02-01

361413 276875 1,793 46 20 41 citations h-index g-index papers 47 47 47 1701 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nature Reviews Microbiology, 2007, 5, 540-553.	28.6	303
2	Shigella Isolates From the Global Enteric Multicenter Study Inform Vaccine Development. Clinical Infectious Diseases, 2014, 59, 933-941.	5 . 8	297
3	Progress and pitfalls in Shigella vaccine research. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 245-255.	17.8	117
4	Deletion in theShigellaEnterotoxin Genes Further AttenuatesShigella flexneri2a Bearing Guanine Auxotrophy in a Phase 1 Trial of CVD 1204 and CVD 1208. Journal of Infectious Diseases, 2004, 190, 1745-1754.	4.0	86
5	Safety and Immunogenicity of CVD 1208S, a Live, Oral <i>î"guaBA î"sen î"set Shigella flexneri</i> 2a Vaccine Grown on Animal-Free Media. Hum Vaccin, 2007, 3, 268-275.	2.4	72
6	Evaluating Shigella flexneri Pathogenesis in the Human Enteroid Model. Infection and Immunity, 2019, 87, .	2.2	71
7	Genomic diversity of EPEC associated with clinical presentations of differing severity. Nature Microbiology, 2016, 1, 15014.	13.3	66
8	Analysis of Shigella flexneri Resistance, Biofilm Formation, and Transcriptional Profile in Response to Bile Salts. Infection and Immunity, 2017, 85, .	2.2	65
9	Immune responses elicited against multiple enterotoxigenic Escherichia coli fimbriae and mutant LT expressed in attenuated Shigella vaccine strains. Vaccine, 2003, 21, 333-340.	3 . 8	58
10	Characterization of rationally attenuated Francisella tularensis vaccine strains that harbor deletions in the guaA and guaB genes. Vaccine, 2009, 27, 2426-2436.	3.8	40
11	Vaccines against Tularemia. Hum Vaccin, 2009, 5, 832-838.	2.4	33
12	Live Attenuated Mutants of Francisella tularensis Protect Rabbits against Aerosol Challenge with a Virulent Type A Strain. Infection and Immunity, 2014, 82, 2098-2105.	2.2	32
13	Differential Growth of Francisella tularensis, Which Alters Expression of Virulence Factors, Dominant Antigens, and Surface-Carbohydrate Synthases, Governs the Apparent Virulence of Ft SchuS4 to Immunized Animals. Frontiers in Microbiology, 2017, 8, 1158.	3.5	32
14	Genetic Characterization and Immunogenicity of Coli Surface Antigen 4 from Enterotoxigenic Escherichia coli when It Is Expressed in a Shigella Live-Vector Strain. Infection and Immunity, 2003, 71, 1352-1360.	2.2	28
15	Formulation and Stabilization of Francisella tularensis Live Vaccine Strain. Journal of Pharmaceutical Sciences, 2011, 100, 3076-3087.	3.3	28
16	Live Attenuated Shigella dysenteriae Type 1 Vaccine Strains Overexpressing Shiga Toxin B Subunit. Infection and Immunity, 2011, 79, 4912-4922.	2.2	28
17	Vaccines Against Shigella and Enterotoxigenic Escherichia coli: A summary of the 2018 VASE Conference. Vaccine, 2019, 37, 4768-4774.	3.8	28
18	A Novel <i>Shigella</i> Proteome Microarray Discriminates Targets of Human Antibody Reactivity following Oral Vaccination and Experimental Challenge. MSphere, 2018, 3, .	2.9	27

#	Article	IF	CITATIONS
19	Tick extracellular vesicles enable arthropod feeding and promote distinct outcomes of bacterial infection. Nature Communications, 2021, 12, 3696.	12.8	27
20	Research in a time of enteroids and organoids: how the human gut model has transformed the study of enteric bacterial pathogens. Gut Microbes, 2020, 12, 1795389.	9.8	26
21	Genome and Functional Characterization of Colonization Factor Antigen I- and CS6-Encoding Heat-Stable Enterotoxin-Only Enterotoxigenic Escherichia coli Reveals Lineage and Geographic Variation. MSystems, 2019, 4, .	3.8	25
22	Anti-CfaE nanobodies provide broad cross-protection against major pathogenic enterotoxigenic Escherichia coli strains, with implications for vaccine design. Scientific Reports, 2021, 11, 2751.	3.3	23
23	Pathogenomic analyses of Shigella isolates inform factors limiting shigellosis prevention and control across LMICs. Nature Microbiology, 2022, 7, 251-261.	13.3	23
24	Gut-Homing Conventional Plasmablasts and CD27− Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans. Frontiers in Immunology, 2014, 5, 374.	4.8	21
25	Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune Bovine Colostrum Products. Vaccine Journal, 2017, 24, .	3.1	21
26	A roadmap for enterotoxigenicEscherichia colivaccine development based on volunteer challenge studies. Human Vaccines and Immunotherapeutics, 2019, 15, 1357-1378.	3.3	20
27	A bivalent vaccine confers immunogenicity and protection against Shigella flexneri and enterotoxigenic Escherichia coli infections in mice. Npj Vaccines, 2020, 5, 30.	6.0	20
28	Identification and Characterization of Human Monoclonal Antibodies for Immunoprophylaxis against Enterotoxigenic Escherichia coli Infection. Infection and Immunity, 2018, 86, .	2.2	18
29	A tale of two bacterial enteropathogens and one multivalent vaccine. Cellular Microbiology, 2019, 21, e13067.	2.1	16
30	Characterization of Francisella tularensis Schu S4 defined mutants as live-attenuated vaccine candidates. Pathogens and Disease, 2015, 73, ftv036.	2.0	15
31	Characterization of a multicomponent live, attenuated <i>Shigella flexneri < /i>vaccine. Pathogens and Disease, 2016, 74, ftw034.</i>	2.0	15
32	A new human challenge model for testing heat-stable toxin-based vaccine candidates for enterotoxigenic Escherichia coli diarrhea – dose optimization, clinical outcomes, and CD4+ T cell responses. PLoS Neglected Tropical Diseases, 2019, 13, e0007823.	3.0	15
33	Biochemical and Immunological Evaluation of Recombinant CS6-Derived Subunit Enterotoxigenic Escherichia coli Vaccine Candidates. Infection and Immunity, 2019, 87, .	2.2	15
34	The synthesis of OspD3 (ShET2) in <i>Shigella flexneri</i> is independent of OspC1. Gut Microbes, 2016, 7, 486-502.	9.8	14
35	Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity. Vaccine Journal, 2017, 24, .	3.1	11
36	Experimental Infection of Human Volunteers with the Heat-Stable Enterotoxin-Producing Enterotoxigenic Escherichia coli Strain TW11681. Pathogens, 2019, 8, 84.	2.8	11

3

#	Article	IF	CITATIONS
37	Aerosol prime-boost vaccination provides strong protection in outbred rabbits against virulent type A Francisella tularensis. PLoS ONE, 2018, 13, e0205928.	2.5	10
38	Characterization of Schu S4 <i>aro</i> mutants as live attenuated tularemia vaccine candidates. Virulence, 2020, 11, 283-294.	4.4	7
39	Deletion of the Major Facilitator Superfamily Transporter fptB Alters Host Cell Interactions and Attenuates Virulence of Type A Francisella tularensis. Infection and Immunity, 2018, 86, .	2.2	6
40	Evaluation of a Live Attenuated S. sonnei Vaccine Strain in the Human Enteroid Model. Pathogens, 2021, 10, 1079.	2.8	5
41	The O-Ag Antibody Response to Francisella Is Distinct in Rodents and Higher Animals and Can Serve as a Correlate of Protection. Pathogens, 2021, 10, 1646.	2.8	5
42	Simple method for purification of enterotoxigenic Escherichia coli fimbriae. Protein Expression and Purification, 2016, 119, 130-135.	1.3	4
43	Identification of an Attenuated Substrain of Francisella tularensis SCHU S4 by Phenotypic and Genotypic Analyses. Pathogens, 2021, 10, 638.	2.8	2
44	Deletion Mutants of Francisella Phagosomal Transporters FptA and FptF Are Highly Attenuated for Virulence and Are Protective Against Lethal Intranasal Francisella LVS Challenge in a Murine Model of Respiratory Tularemia. Pathogens, 2021, 10, 799.	2.8	2
45	Sequence variations in the ETEC CS6 operon affect transcript and protein expression. Virulence, 2021, 12, 2659-2669.	4.4	2
46	Live Attenuated Vectors: Have they Delivered?. , 0, , 72-86.		0